# KOTAI Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kotai-biotechnologies

- Industry: Pharmaceuticals
- Headquarters: Suita-shi, Japan
- Website: www.kotai-bio.com
- Total disclosed funding: $3.4M
- Latest round: Series C (Oct 30, 2018)
- Investors on record: 1

## About

Based in Osaka, Japan, established in 2016, KOTAI Biotechnologies provides an immunity AI platform and analyzes related data. 
In 2016, the company started business at Research Institute for Microbial Diseases, Osaka University. Immediately underwent fundraising in 2016 and 2017. Also underwent fundraising in 2019 and 2020. The company has received several grants and subsidies from AMED (Japan Agency for Medical Research and Development) since 2018 to the present to fund researches. 
Kotai Biotech finds receptor groups that only certain people have, such as patients with a specific disease or patients who are effective for a certain drug, among the vast variety of immune repertoires. This can be used to find very rare and important receptors, or to analyze thousands of people on the contrary. These analyses are only possible with our unique AI analysis. Therefore, it is very novel and unique. Kotai Biotech is researching whether the receptors and receptor groups found here can be used as new drug targets and biomarkers. 
Kotai Biotech is focusing on the field of cancer and autoimmune diseases. In addition, it is conducting researches in the field of infectious diseases under the grants from Japan Agency for Medical Research and Development (AMED). 
Kotai Biotech conducts joint research and development with pharmaceutical companies and bio-related companies. Not only repertoire analysis, but also our experts will help the customer succeed in their research and development by combining Kotai Biotech's own immune informatics (AI technology, Structure Simulation, etc.) and experimental technology (single cell NGS analysis, etc.) The theme should be set for each individual company, such as search for drug discovery targets for each disease, patient stratification, and the development of diagnostic methods. Kotai Biotech asks the companies involved joint research and development to bear joint research expenses (such as our R&D expenses, success compensation, etc.) and share the intellectual property.

## Funding rounds

- Series C, Oct 30, 2018, $1.8M — Osaka University Venture Capital
- Series B, Apr 21, 2017, $1.1M — Osaka University Venture Capital
- Series A, Oct 21, 2016, $0.5M — Osaka University Venture Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A, Series B, Series C